Journal of Stem Cells and Regenerative Medicine
 
 
Vol.V  Issue: 2: (JSRM code: 005020700006)

Full Text pdf

   

In vitro production of RBCs from ES, iPS & Stem cell banking in Japan
Yukio Nakamura*
(PASRM** 2009-003)

RIKEN BioResource Center, Koyadai 3-1-1, Tsukuba, Ibaraki, Japan

 
     

The supply of transfusable red blood cells (RBCs) is not sufficient in many countries. If erythroid cell lines able to produce transfusable RBCs in vitro were established, they would be valuable resources. However, such cell lines have not been established.

We developed a robust method to obtain differentiated cell lines following the induction of hematopoietic differentiation of mouse embryonic stem (ES) cells and established five independent hematopoietic cell lines using the method. Three of these lines exhibited characteristics of erythroid cells. Although their precise characteristics varied, each of these lines could differentiate in vitro into more mature erythroid cells, including enucleated RBCs. Following transplantation of these erythroid cells into mice suffering from acute anemia, the cells proliferated transiently, subsequently differentiated into functional RBCs, and significantly ameliorated the acute anemia.

Considering the number of human ES and induced pluripotent stem (iPS) cell lines that have been established so far, the intensive testing of a number of these lines for erythroid potential may allow the establishment of human erythroid cell lines similar to the mouse erythroid cell lines. In addition, our results strongly suggest the possibility of establishing useful cell lines committed to specific lineages other than hematopoietic progenitors from human ES and iPS cells.

The Cell Engineering Division of RIKEN BioResource Center is a not-for-profit public “Cell Bank” that accepts donation and deposit of human and animal cell materials developed by life science research community. We examine, standardize, amplify, preserve, and provide cell materials to the scientists around the world.

The stem cells such as ES cells and iPS cells are valuable in current biology and medical sciences. Thus, we are collecting such stem cell lines and aiming to contribute to the fields of developmental biology, transplantation medicine, regenerative medicine, and so on.

** Proceedings of Annual Symposium on Regenerative Medicine

 
               
 

Dr. Yukio Nakamura,
Division Director Cell Engineering Division,
RIKEN BioResource Center
Koyadai 3-1-1, Tsukuba,
Ibaraki, 305-0074, Japan .

         
                 
Copyright © Journal of Stem Cells & Regenerative Medicine. All rights reserved.
Disclaimer